CDK4 and triple-negative breast carcinoma: The results of this study may be used as a baseline to gauge the real-world effect of new treatments targeting MBC introduced after the study period, such as the CDK4/6- and PI3K-inhibitors targeting HR-positive MBC, and immunotherapy for triple-negative breast cancer.